Rheonix

About Rheonix

Rheonix Inc. operates as a key developer in the molecular diagnostics sector, providing automated solutions designed to simplify complex testing procedures. The Ithaca, New-York based company was founded in 2008 by serial entrepreneur Greg Galvin, Ph.D. Galvin, who holds a Ph.D. in materials science and an MBA from Cornell University, launched Rheonix to capitalize on opportunities in the diagnostics industry after his previous venture, Kionix, had explored microfluidics technology. His background, which merges deep scientific knowledge with business acumen, has been central to the company's direction.

The company's core business revolves around its Encompass family of workstations (Encompass MDx® for clinical diagnostics and Encompass Optimum™ for applied markets like food and beverage safety), which are fully automated, sample-to-answer platforms. Revenue is generated from the sale of these workstations and the accompanying proprietary, single-use Rheonix CARD® cartridges. This model targets a broad client base, from small and medium-sized hospital laboratories to large reference labs and applied testing facilities, by offering a low-cost, easy-to-use system that requires minimal technical skill to operate.

The patented Rheonix CARD® cartridge is a critical component, functioning as a disposable, microfluidic "lab-on-a-chip." It integrates all stages of a molecular assay—including sample preparation, nucleic acid extraction, purification, amplification (like PCR), and detection—into a single, enclosed, credit-card-sized device. This design minimizes manual intervention, reduces the potential for contamination, and streamlines laboratory workflows. The Encompass workstations automate the entire process by controlling the movement of fluids and reagents within the CARD, processing up to 24 samples simultaneously. A significant milestone was achieved during the COVID-19 pandemic when Rheonix received FDA Emergency Use Authorization (EUA) for its COVID-19 MDx assay, showcasing the platform's rapid adaptability and relevance in public health crises. Following this, in 2022, the company secured full 510(k) clearance from the FDA for its Encompass MDx workstation and an STI TriPlex Assay for detecting sexually transmitted infections.